Also found in: Dictionary, Thesaurus, Wikipedia.
Related to Sarafem: Zoloft, PMDD

fluoxetine hydrochloride

Prozac, Prozac Weekly, Prozit (UK), Sarafem

Pharmacologic class: Selective serotonin reuptake inhibitor

Therapeutic class: Antidepressant

Pregnancy risk category B


Selectively inhibits serotonin reuptake in CNS; has little to no effect on norepinephrine and dopamine reuptake


Capsules: 10 mg, 15 mg, 20 mg, 40 mg

Capsules (delayed-release): 90 mg

Oral solution: 20 mg/5 ml

Tablets: 10 mg, 15 mg, 20 mg

Indications and dosages

Major depressive disorder (MDD)

Adults: 20 mg/day P.O. in morning. After several weeks, may increase by 20 mg/day at weekly intervals. Give dosages above 20 mg/day in two divided doses (morning and noon); don't exceed 80 mg/day. Patients stabilized on 20 mg/day may be switched to 90-mg/week delayed-release capsules (Prozac Weekly) 7 days after last 20-mg dose.

Children ages 8 to 18: Initially, 10 to 20 mg/day P.O. After 1 week at 10 mg daily, dosage should be increased to 20 mg/day. However, because of higher plasma levels in lower-weight children, starting and target dose in this group may be 10 mg/day. Dosage increase to 20 mg/day may be considered after several weeks if insufficient clinical improvement occurs.

Obsessive-compulsive disorder (OCD)

Adults: Initially, 20 mg/day P.O. in morning. After several weeks, may increase dosage. Give doses above 20 mg/day once daily (morning) or in two divided doses b.i.d. (morning and noon). Dosage range of 20 to 60 mg/day is recommended; however, dosages of up to 80 mg/day have been well tolerated. Don't exceed 80 mg/day.

Children ages 7 to 17: Initially, 10 mg/day P.O. in morning in adolescents and higher-weight children; after 2 weeks, may increase dosage to 20 mg/day. Additional dosage increases may be considered after several more weeks if insufficient clinical improvement occurs. Dosage range of 20 to 60 mg/day is recommended. Initially, 10 mg/day P.O. in lower-weight children; may increase dosage after several more weeks if insufficient clinical improvement occurs. Dosage range of 20 to 30 mg/day is recommended. Experience with daily doses greater than 20 mg is very minimal; there is no experience with doses greater than 60 mg.

Acute treatment of depressive episodes associated with bipolar I disorder

Adults: Initially, 20 mg fluoxetine P.O. with 5 mg olanzapine P.O. daily; dosage range of fluoxetine is 20 to 50 mg; olanzapine, 5 to 12.5 mg. Safety of fluoxetine doses above 75 mg and olanzapine doses above 18 mg haven't been established

Bulimia nervosa

Adults: 60 mg/day P.O.; may be titrated upward over several days

Panic disorder

Adults: 10 mg/day P.O. for 1 week; then, if needed, increase to 20 mg/day. Dosage increases of up to 60 mg/day may be considered after several weeks if patient doesn't respond to lower dosage.

Premenstrual dysphoric disorder

Adults: 20 mg/day (Sarafem) P.O., not to exceed 80 mg/day

Dosage adjustment

• Hepatic impairment

• Concurrent disease or multiple concomitant medications

• Pregnant women during third trimester

• Elderly patients

Off-label uses

• Diabetic peripheral neuropathy

• Alcoholism

• Bipolar II disorder

• Borderline personality disorder

• Narcolepsy

• Posttraumatic stress disorder

• Schizophrenia

• Social phobia


• Hypersensitivity to drug

• MAO inhibitor use within past 14 days

• Concurrent use of thioridazine or within 5 weeks of discontinuing fluoxetine

• Concurrent use of pimozide


Use cautiously in:

• hepatic or renal impairment, diabetes mellitus, cardiovascular disease, concomitant illness, acute narrow-angle glaucoma

• history of seizures, serotonin syndrome or neuroleptic malignant syndrome, clinical worsening and suicidal thinking and behavior, activation of mania or hypomania

• hyponatremia in association with syndrome of inappropriate antidiuretic hormone secretion

• concurrent use of NSAIDs, aspirin, warfarin, or other drugs that affect coagulation

• concurrent use of tryptophan (use not recommended)

• pregnant patients (third trimester)

• breastfeeding patients (use not recommended)

• children younger than age 7 (in OCD use), younger than age 8 (in MDD use), younger than age 18 for all other uses (safety and efficacy not established).


Be aware that drug should be discontinued 5 weeks before MAO inhibitor or thioridazine therapy begins.

• Give before 2 P.M. to prevent nighttime insomnia.

• Be aware that drug should be gradually reduced rather than abruptly stopped whenever possible.

Adverse reactions

CNS: anxiety, drowsiness, headache, insomnia, abnormal dreams, dizziness, fatigue, nervousness, hypomania, mania, weakness, tremor, seizures, suicidal ideation

CV: chest pain, palpitations, prolonged QTc interval

EENT: visual disturbances, stuffy nose, sinusitis, pharyngitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dry mouth, anorexia

GU: urinary frequency, sexual dysfunction, dysmenorrhea

Metabolic: hypouricemia, hypocalcemia, hyponatremia, hyperglycemia, hypoglycemia

Musculoskeletal: joint, back, or muscle pain

Respiratory: cough, upper respiratory tract infection, dyspnea, respiratory distress

Skin: diaphoresis, pruritus, erythema nodosum, flushing, rash

Other: abnormal taste, weight loss, fever, flulike symptoms, hot flashes, serotonin syndrome, neuroleptic malignant syndrome (NMS), allergic reactions, hypersensitivity reactions


Drug-drug. Adrenergics: increased sensitivity to adrenergics, increased risk of serotonin syndrome

Alprazolam: decreased metabolism and increased effects of alprazolam

Antihistamines, opioids, other antidepressants, sedative-hypnotics: additive CNS depression

Aspirin, NSAIDs, warfarin, other drugs that affect coagulation: increased risk of GI or other bleeding

Buspirone: potentiation of fluoxetine effects, increased risk of seizures

Carbamazepine, clozapine, digoxin, haloperidol, lithium, phenytoin, warfarin: increased blood levels of these drugs, greater risk of adverse reactions

CYP450-2D6 inducers: increased effects of these drugs

Cyproheptadine: decrease in or reversal of fluoxetine effects

Digoxin, warfarin, other highly protein-bound drugs: increased risk of adverse reactions to either drug

Efavirenz, ritonavir, saquinavir, other CYP450 inhibitors: serotonergics, triptans: increased risk of serotonin syndrome

MAO inhibitors: confusion, agitation, seizures, hypertension, and hyperpyrexia (serotonin syndrome)

Pimozide: increased risk of drug interaction or QTc-interval prolongation

Thioridazine: increased risk of QTc-interval prolongation or potential for elevated thioridazine plasma level

Other antidepressants, phenothiazines, risperidone, tryptophan: increased risk of adverse reactions

Ritonavir: increased ritonavir blood level

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, blood urea nitrogen, creatine kinase, electrolytes, glucose: increased levels

Sodium: decreased level

Drug-herbs. St. John's wort: increased risk of serotonin syndrome

Drug-behaviors. Alcohol use: additive CNS depression

Patient monitoring

Monitor patient for signs and symptoms of depression. Assess for suicidal ideation.

Evaluate neurologic status, watching especially for seizures.

Monitor cardiovascular status, particularly for prolonged QTc interval.

• Assess weight regularly. Watch for signs of eating disorders.

Monitor patient for signs and symptoms of allergic reactions, serotonin syndrome, or NMS-like reactions. Discontinue drug immediately and initiate supportive treatment if these reactions occur.

Patient teaching

• Encourage patient to establish effective bedtime routine to minimize sleep disorders.

• Tell patient drug may take 4 weeks or longer to be fully effective.

Instruct patient to contact prescriber if he develops worsening depression or has suicidal thoughts.

Instruct patient to immediately stop drug and report signs and symptoms of allergic reactions (rash), serotonin syndrome, or neuroleptic malignant syndrome-like reactions.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• Tell female patient to inform prescriber if she is pregnant or breastfeeding.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


(floo-ox-uh-teen) ,


(trade name),

PROzac Weekly

(trade name),


(trade name)


Therapeutic: antidepressants
Pharmacologic: selective serotonin reuptake inhibitors ssris
Pregnancy Category: C


Major depressive disorder.Obsessive compulsive disorder (OCD).Bulimia nervosa.Panic disorder.Acute treatment of depressive episodes associated with bipolar I disorder (when used with olanzapine).Treatment-resistant depression (when used with olanzapine).Sarafem: Premenstrual dysphoric disorder (PMDD).Anorexia nervosa:
  • ADHD,
  • Diabetic neuropathy,
  • Fibromyalgia,
  • Obesity,
  • Raynaud’s phenomenon,
  • Social anxiety disorder (social phobia),
  • Posttraumatic stress disorder (PTSD).


Selectively inhibits the reuptake of serotonin in the CNS.

Therapeutic effects

Antidepressant action.
Decreased behaviors associated with:
  • panic disorder,
  • bulimia.
Decreased mood alterations associated with PMDD.


Absorption: Well absorbed after oral administration.
Distribution: Crosses the blood-brain barrier.
Protein Binding: 94.5%.
Metabolism and Excretion: Converted by the liver to norfluoxetine (primarily by CYP2D6 isoenzyme), another antidepressant compound; genetic implication the CYP2D6 enzyme system exhibits genetic polymorphism (∼7% of population may be poor metabolizers and may have significantly ↑ fluoxetine concentrations and an ↑ risk of adverse effects). Fluoxetine and norfluoxetine are mostly metabolized by the liver; 12% excreted by kidneys as unchanged fluoxetine, 7% as unchanged norfluoxetine.
Half-life: 1–3 days (norfluoxetine 5–7 days).

Time/action profile (antidepressant effect)

PO1–4 wkunknown2 wk


Contraindicated in: Hypersensitivity;Concurrent use of MAO inhibitors or MAO-like drugs (linezolid or methylene blue);Concurrent use of pimozide;Concurrent use of thioridazine (fluoxetine should be discontinued at least 5 wk before thioridazine therapy is initiated).
Use Cautiously in: History of seizures;Debilitated patients (↑ risk of seizures);Diabetes mellitus;Patients with concurrent chronic illness or multiple drug therapy (dose adjustments may be necessary);Hepatic impairment (↓ doses/↑ dosing interval may be necessary);May ↑ risk of suicide attempt/ideation especially during early treatment or dose adjustment;Patients with ↑ intraocular pressure or at risk for acute narrow-angle glaucoma;Congenital long QT syndrome, history of QT interval prolongation, family history of long QT syndrome or sudden cardiac death, concurrent use of QT interval prolonging drugs, hypokalemia, hypomagnesemia, recent MI, uncompensated HF, or bradycardia; Obstetric: Use during first trimester may ↑ risk of cardiovascular malformations in infant. Use during third trimester may result in neonatal serotonin syndrome requiring prolonged hospitalization, respiratory and nutritional support. May cause sedation in infant. Use only if potential benefit justifies potential risk to fetus; Lactation: May cause sedation in infant; discontinue drug or bottle-feed; Pediatric: Risk of suicide ideation or attempt may be greater in children or adolescents (safe use in children <7 yr not established); Geriatric: Appears on Beers list. Geriatric patients are at ↑ risk for excessive CNS stimulation, sleep disturbances, and agitation.

Adverse Reactions/Side Effects

Central nervous system

  • neuroleptic malignant syndrome (life-threatening)
  • seizures (life-threatening)
  • suicidal thoughts (life-threatening)
  • anxiety (most frequent)
  • drowsiness (most frequent)
  • headache (most frequent)
  • insomnia (most frequent)
  • nervousness (most frequent)
  • abnormal dreams
  • dizziness
  • fatigue
  • hypomania
  • mania
  • weakness

Ear, Eye, Nose, Throat

  • mydriasis
  • stuffy nose
  • visual disturbances


  • cough


  • torsades de pointes (life-threatening)
  • chest pain
  • palpitations
  • QT interval prolongation


  • diarrhea (most frequent)
  • abdominal pain
  • abnormal taste
  • anorexia
  • constipation
  • dry mouth
  • dyspepsia
  • nausea
  • vomiting
  • weight loss


  • sexual dysfunction (most frequent)
  • urinary frequency


  • ↑ sweating (most frequent)
  • pruritus (most frequent)
  • erythema nodusum
  • flushing
  • rashes


  • dysmenorrhea

Fluid and Electrolyte

  • hyponatremia


  • arthralgia
  • back pain
  • myalgia


  • tremor (most frequent)


  • serotonin syndrome (life-threatening)
  • allergic reactions
  • fever
  • flu-like syndrome
  • hot flashes
  • sensitivity reaction


Drug-Drug interaction

Discontinue use of MAO inhibitors for 14 days before fluoxetine therapy; combined therapy may result in confusion, agitation, seizures, hypertension, and hyperpyrexia (serotonin syndrome). Fluoxetine should be discontinued for at least 5 wk before MAO inhibitor therapy is initiated.Concurrent use with MAO-inhibitor-like drugs, such as linezolid or methylene blue may ↑ risk of serotonin syndrome; concurrent use contraindicated; do not start therapy in patients receiving linezolid or methylene blue ; if linezolid or methylene blue need to be started in a patient receiving fluoxetine, immediately discontinue fluoxetine and monitor for signs/symptoms of serotonin syndrome for 2 wk or until 24 hr after last dose of linezolid or methylene blue, whichever comes first (may resume fluoxetine therapy 24 hr after last dose of linezolid or methylene blue)Concurrent use with pimozide may ↑ risk of QT interval prolongation.↑ levels of thioridazine may ↑ risk of QT interval prolongation (concurrent use contraindicated; fluoxetine should be discontinued for at least 5 wk before thioridazine is initiated).QT interval prolonging drugs may ↑ the risk of QT interval prolongation with arrhythmias; avoid concurrent useInhibits the activity of cytochrome P450 2D6 enzyme in the liver and ↑ effects of drugs metabolized by this enzyme system.Medications that inhibit the P450 enzyme system (including ritonavir, saquinavir, and efavirenz ) may ↑ risk of developing the serotonin syndrome). For concurrent use with ritonavir ↓ fluoxetine dose by 70%; if initiating fluoxetine, start with 10 mg/day dose.↓ metabolism and ↑ effects of alprazolam (decrease alprazolam dose by 50%).Drugs that affect serotonergic neurotransmitter systems, including tricyclic antidepressants, SNRIs, fentanyl, buspirone, tramadol, and triptans ↑ risk of serotonin syndrome↑ CNS depression with alcohol, antihistamines, other antidepressants, opioid analgesics, or sedative/hypnotics.↑ risk of side effects and adverse reactions with other antidepressants, risperidone, or phenothiazines.May ↑ effectiveness/risk of toxicity from carbamazepine, clozapine, digoxin, haloperidol, phenytoin, lithium, or warfarin.May ↓ the effects of buspirone.Cyproheptadine may ↓ or reverse effects of fluoxetine.May ↑ sensitivity to adrenergics and increase the risk of serotonin syndrome.May alter the activity of other drugs that are highly bound to plasma proteins.↑ risk of serotonin syndrome with 5HT1 agonists.↑ risk of bleeding with NSAIDS, aspirin, clopidogrel, or warfarin.↑ risk of serotonin syndrome with St. John’s wort and SAMe.


Oral (Adults) Depression, OCD—20 mg/day in the morning. After several weeks, may ↑ by 20 mg/day at weekly intervals. Doses greater than 20 mg/day should be given in 2 divided doses, in the morning and at noon (not to exceed 80 mg/day). Patients who have been stabilized on the 20 mg/day dose may be switched over to delayed-release capsules (Prozac Weekly) at dose of 90 mg weekly, initiated 7 days after the last 20-mg dose. Panic disorder—10 mg/day initially, may ↑ after 1 week to 20 mg/day (usual dose is 20 mg, but may be ↑ as needed/tolerated up to 60 mg/day). Bulimia nervosa—60 mg/day (may need to titrate up to dosage over several days). PMDD—20 mg/day (not to exceed 80 mg/day) or 20 mg/day starting 14 days prior to expected onset on menses, continued through first full day of menstruation, repeated with each cycle. Depressive episodes associated with bipolar I disorder—20 mg/day with olanzapine 5 mg/day (both given in evening); may ↑ fluoxetine dose up to 50 mg/day and olanzapine dose up to 12.5 mg/day; Treatment-resistant depression—20 mg/day with olanzapine 5 mg/day (both given in evening); may ↑ fluoxetine dose up to 50 mg/day and olanzapine dose up to 20 mg/day.
Oral (Geriatric Patients) Depression—10 mg/day in the morning initially, may be ↑ (not to exceed 60 mg/day).
Oral (Children 7–17 yr) Depression and OCD (adolescents and higher weight children)—10 mg/day may be ↑ after 2 wk to 20 mg/day; additional increases may be made after several more weeks (range 20–60 mg/day); Depression and OCD (lower-weight children)—10 mg/day initially, may be ↑ after several more weeks (range 20–30 mg/day).
Oral (Children 10–17 yr) Depressive episodes associated with bipolar I disorder—20 mg/day with olanzapine 2.5 mg/day (both given in evening); may ↑ fluoxetine dose up to 50 mg/day and olanzapine dose up to 12 mg/day.

Availability (generic available)

Tablets: 10 mg, 15 mg, 20 mg Cost: Generic — 20 mg $73.03 / 100
Capsules: 10 mg, 20 mg, 40 mg Cost: Generic — 10 mg $10.83 / 100, 20 mg $8.62 / 100, 40 mg $41.03 / 100
Delayed-release capsules (Prozac Weekly): 90 mg Cost: Generic — $147.96 / 4
Oral solutionmint flavor: 20 mg/5 mL Cost: Generic — $118.00 / 120 mL
In combination with: olanzapine (Symbyax; see combination drugs).

Nursing implications

Nursing assessment

  • Monitor mood changes. Inform health care professional if patient demonstrates significant increase in anxiety, nervousness, or insomnia.
    • Assess for suicidal tendencies, especially during early therapy. Restrict amount of drug available to patient. Risk may be increased in children, adolescents, and adults ≤24 yr. After starting therapy, children, adolescents, and young adults should be seen by health care professional at least weekly for 4 wk, every 3 wk for next 4 wk, and on advice of health care professional thereafter.
    • Monitor appetite and nutritional intake. Weigh weekly. Notify health care professional of continued weight loss. Adjust diet as tolerated to support nutritional status.
    • Assess for sensitivity reaction (urticaria, fever, arthralgia, edema, carpal tunnel syndrome, rash, hives, lymphadenopathy, respiratory distress) and notify health care professional if present; symptoms usually resolve by stopping fluoxetine but may require administration of antihistamines or corticosteroids.
  • Assess for sexual side effects (erectile dysfunction; decreased libido).
  • Monitor for development of neuroleptic malignant syndrome (fever, respiratory distress, tachycardia, seizures, diaphoresis, arrhythmias, hypertension or hypotension, pallor, tiredness, severe muscle stiffness, loss of bladder control). Report immediately.
  • Assess for serotonin syndrome (mental changes [agitation, hallucinations, coma], autonomic instability [tachycardia, labile BP, hyperthermia], neuromuscular aberrations [hyperreflexia, incoordination], and/or GI symptoms [nausea, vomiting, diarrhea]), especially in patients taking other serotonergic drugs (SSRIs, SNRIs, triptans).
  • OCD: Assess for frequency of obsessive-compulsive behaviors. Note degree to which these thoughts and behaviors interfere with daily functioning.
  • Bulimia Nervosa: Assess frequency of binge eating and vomiting during therapy.
  • PMDD: Monitor mood prior to and periodically during therapy.
  • Lab Test Considerations: Monitor CBC and differential periodically during therapy. Notify health care professional if leukopenia, anemia, thrombocytopenia, or increased bleeding time occurs.
    • Proteinuria and mild ↑ in AST may occur during sensitivity reactions.
    • May cause ↑ in serum alkaline phosphatase, ALT, BUN, creatine phosphokinase, hypouricemia, hypocalcemia, hypoglycemia or hyperglycemia, and hyponatremia.
    • May cause hypoglycemia in patient with diabetes.

Potential Nursing Diagnoses

Ineffective coping (Indications)
Risk for injury (Side Effects)
Sexual dysfunction (Side Effects)


  • Do not confuse fluoxetine with duloxetine, paroxetine, or Loxitane (loxapine). Do not confuse Prozac with Prilosec (omeprazole), Prograf (tacrolimus), or Provera (medroxyprogesterone). Do not confuse Sarafem (fluoxetine) with Serophene (clomiphene).
  • Oral: Administer as a single dose in the morning. Some patients may require increased amounts, in divided doses, with a 2nd dose at noon.
    • May be administered with food to minimize GI irritation. Do not open, dissolve, chew, or crush delayed-release capsules.

Patient/Family Teaching

  • Instruct patient to take fluoxetine as directed. Take missed doses as soon as remembered unless almost time for next dose, then omit and return to regular schedule. Do not double doses or discontinue without consulting health care professional; discontinuation may cause anxiety, insomnia, nervousness.
  • May cause drowsiness, dizziness, impaired judgment, and blurred vision. Caution patient to avoid driving and other activities requiring alertness until response to the drug is known.
  • Advise patient, family, and caregivers to look for suicidality, especially during early therapy or dose changes. Notify health care professional immediately if thoughts about suicide or dying, attempts to commit suicide, new or worse depression or anxiety, agitation or restlessness, panic attacks, insomnia, new or worse irritability, aggressiveness, acting on dangerous impulses, mania, or other changes in mood or behavior or if symptoms of serotonin syndrome occur.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications. Advise patient to avoid taking other CNS depressants or alcohol.
  • Caution patient to change positions slowly to minimize dizziness.
  • Inform patient that frequent mouth rinses, good oral hygiene, and sugarless gum or candy may minimize dry mouth. If dry mouth persists for more than 2 wk, consult health care professional regarding use of saliva substitute.
  • Caution patient to wear protective clothing and use sunscreen to prevent photosensitivity reactions.
  • Inform patient that medication may cause decreased libido.
  • Advise patient to notify health care professional if symptoms of sensitivity reaction occur or if headache, nausea, anorexia, anxiety, or insomnia persists.
  • Instruct female patients to inform health care professional if pregnancy is planned or suspected, or if breast feeding.
  • Emphasize the importance of follow-up exams to monitor progress.

Evaluation/Desired Outcomes

  • Increased sense of well-being.
    • Renewed interest in surroundings. May require 1–4 wk of therapy to obtain antidepressant effects.
  • Decrease in obsessive-compulsive behaviors.
  • Decrease in binge eating and vomiting in patients with bulimia nervosa.
  • Decreased incidence frequency of panic attacks.
  • Decreased mood alterations associated with PMDD.
Drug Guide, © 2015 Farlex and Partners


A trademark for the drug fluoxetine hydrochloride.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.
References in periodicals archive ?
Selling Sarafem: Priestly and bardic discourses in the construction of premenstrual syndrome.
But in the rush to legitimize more mental "illnesses" and administer mind-altering drugs to as many people as possible, Lilly opted for Sarafem, a dead-ringer, it turns out, for Prozac, with the same empirical formula (reprinted in O'Meara's book).
When Lilly was still marketing the drug, the "physician information" section of its Web site for Sarafem said that "fluoxetine was initially developed and marketed as an antidepressant (Prozac, fluoxetine hydrochloride)," while patients were told, in their section of the Web site, that "Sarafem contains fluoxetine hydrochloride, the same active ingredient found in Prozac."
Food and Drug Administration has already approved two such drugs to treat PMDD: fluoxetine (Sarafem) and sertraline (Zoloft).
The Food and Drug Administration has approved a prescription formulation of Prozac called Sarafem for severe PMS.
The FDA recently approved the first prescription medication to treat women who experience temporary depression, severe irritability, and lethargy during their menstrual cycles, Sarafem contains fluoxetine hydrochloride, the same active ingredient found in Prozac.
Fluoxetine Capsules, USP, Teva Pharmaceuticals Sarafem Pulvules,
At press time, those changes had been made in the labels for venlafaxine (Effexor and Effexor XR), nefazodone (Serzone), bupropion (Wellbutrin, Zyban), citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), and paroxetine (Paxil).
Galen specialises in women's healthcare products and its success is being attributed to sales of the new contraceptives Estrostep and Loestrn, and Sarafem, used to treat pre-menstrual disorder, which the company acquired through the sale of the US group, Eli Lily.
The company also added Sarafem - a treatment for severe pre-menstrual syndrome - to its product range in January, strengthening its foothold in the rapidly expanding US market.
While investors will be keen to hear more from management on the episode, close attention will also be paid to the performance of newly acquired drug lines such as Sarafem, a treatment for pre-menstrual syndrome, as well as the progress launch of its Femring oestrogen product in the US.
In 2000, the company gained FDA approval to market Prozac as a treatment for the condition; Eli Lilly promptly repackaged Prozac as a pink-coated pill called Sarafem and launched a P.R.